ArriVent BioPharma Inc.
AVBP | NASDAQ
$29.74
+$0.84 (+2.91%)
At close: Sep 21, 2026, 4:00 PM ET
$29.51
-$0.23 (-0.77%)
Pre-market:
Sep 22, 2026, 7:31 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
PE Ratio | -4.66 | -10.41 | -9.22 | -18.18 | -0.49 |
PEG Ratio | -0.07 | -0.58 | -0.09 | 0.19 | n/a |
PS Ratio | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 2.52 | 3.25 | 4.22 | 3.84 | 0.62 |
P/FCF Ratio | -4.82 | -11.94 | -11.45 | -15.35 | -2.03 |
P/OCF Ratio | -4.82 | -11.94 | -11.45 | -15.35 | -2.03 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0 | 0 | 0 | 0 | n/a |
Quick Ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
Current Ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -54.13% | -31.24% | -45.83% | -21.15% | -125.19% |
Return on Assets | -49.92% | -29.27% | -42.51% | -20.19% | -119.91% |
Return on Invested Capital | -57.78% | -36.58% | -49.20% | -21.14% | -21.10% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove AVBP